A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients with VWD

NCT06205095

Status	RECRUITING
Phase	Phase 3
Sponsor	Unity Health Toronto
Enrollment	20 participants

Key Eligibility Criteria

Inclusion (7)

- Patient capable of providing informed consent;
- Female patients with HMB over the age of 18 years, for whom prophylactic treatment with Wilate® is deemed clinically appropriate according to the medical discretion (based on their expert opinion given consideration of the patient's bleeding history and responsiveness to treatment) of the treating hemostasis-focused physician practicing at a Hemophilia Treatment Center;
- Modified PBAC score \> 100 at screening;
- Patients with a diagnosis of inherited von Willebrand disease (any type);
- Stable treatment for HMB and iron deficiency anemia for 3 cycles before entering the study and anticipated to remain unchanged for the duration of the study;

... and 2 more (see full listing online)

Exclusion (11)

- Diagnosed with any other known bleeding disorder;
- Pregnancy or plans to become pregnant within the duration of the study;
- Breastfeeding or plans to breastfeed within the duration of the study;
- Known hypersensitivity reactions to human plasma-derived products or any ingredient in the formulation;
- Known antibodies to VWF or FVIII;

... and 6 more (see full listing online)

Locations (1 total)

St. Michael's Hospital, Toronto, Ontario, Canada